Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Epidemiology and Risk Factors

Article Sidebar

PDF
Published: Jan 10, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i1-08
Keywords:
..

Main Article Content

Alejandra Jeraldine González Barajas
Universidad Autónoma de Guadalajara
Andrea Eyenith Magdaleno Torres
Universidad Autónoma de Guadalajara

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous responses caused by drugs that are characterized by widespread necrosis and epidermal detachment. It is essential to know the risk factors and those agents involved in the development of this pathology in order to use them with caution in susceptible patients and to have a high index of suspicion.

Article Details

How to Cite
González Barajas, A. J. ., & Magdaleno Torres, A. E. . (2023). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Epidemiology and Risk Factors. International Journal of Medical Science and Clinical Research Studies, 3(1), 31–34. https://doi.org/10.47191/ijmscrs/v3-i1-08
Issue
Vol. 3 No. 1 (2023): Volume 03 Issue 01 January 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Alerhand, S., Cassella, C., & Koyfman, A. (2016). Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. Pediatric emergency care, 32(7), 472-476.

II. Sharma, V. K., Sethuraman, G., & Minz, A. (2008). Stevens Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol, 74(8), 238-40.

III. Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B., & Harr, T. (2018). Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clinical reviews in allergy & immunology, 54(1), 147-176.

IV. Sasidharanpillai, S., Riyaz, N., Khader, A., Rajan, U., Binitha, M. P., & Sureshan, D. N. (2015). Severe cutaneous adverse drug reactions: a clinicoepidemiological study. Indian journal of dermatology, 60(1), 102.

V. Fouchard, N., Bertocchi, M., Roujeau, J. C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000). SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. Journal of Investigative Dermatology, 115(2), 149-153.

VI. Sekula, P., Dunant, A., Mockenhaupt, M., Naldi, L., Bavinck, J. N. B., Halevy, S., ... & RegiSCAR Study Group. (2013). Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Journal of Investigative Dermatology, 133(5), 1197-1204.

VII. Halevy, S., Ghislain, P. D., Mockenhaupt, M., Fagot, J. P., Bavinck, J. N. B., Sidoroff, A., ... & EuroSCAR Study Group. (2008). Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. Journal of the American Academy of Dermatology, 58(1), 25-32.

VIII. Tensini, T. S., Von Glehn, C. Q., Bettinotti, M. P., Iglehart, B., de Paola, L., Lohr, A., ... & Silvado, C. E. (2021). Cutaneous adverse reactions associated with antiseizure medication: clinical characteristics and implications in epilepsy treatment. Epileptic Disorders, 23(3), 466-475.

IX. Ferrándiz‐Pulido, C., García‐Fernández, D., Domínguez‐Sampedro, P., & García‐Patos, V. (2011). Stevens‐Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital. Journal of the European Academy of Dermatology and Venereology, 25(10), 1153-1159.

X. Rosen, A. C., Balagula, Y., Raisch, D. W., Garg, V., Nardone, B., Larsen, N., ... & Lacouture, M. E. (2014). Life-threatening dermatologic adverse events in oncology. Anti-cancer drugs, 25(2), 225.

XI. Ramien, M., & Goldman, J. L. (2020). Pediatric SJS-TEN: Where are we now?. F1000Research, 9.

XII. Hung, Y. T., Chen, Y. W., Huang, Y., Lin, Y. J., Chen, C. B., & Chung, W. H. (2022). Acute graft-versus-host disease presenting as Stevens–Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study. Journal of the American Academy of Dermatology.

XIII. Sanabria-Cabrera, J., Medina-Cáliz, I., Stankevičiūtė, S., Rodríguez-Nicolás, A., Almarza-Torres, M., Lucena, M. I., & Andrade, R. J. (2019). Drug-induced liver injury associated with severe cutaneous hypersensitivity reactions: a complex entity in need of a multidisciplinary approach. Current Pharmaceutical Design, 25(36), 3855-3871.

XIV. Peter, J., Choshi, P., & Lehloenya, R. J. (2019). Drug hypersensitivity in HIV infection. Current opinion in allergy and clinical immunology, 19(4), 272.

XV. Chung, W. H., Hung, S. I., & Chen, Y. T. (2007). Human leukocyte antigens and drug hypersensitivity. Current opinion in allergy and clinical immunology, 7(4), 317-323.

XVI. Phillips, E. J., Sukasem, C., Whirl‐Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., ... & Pirmohamed, M. (2018). Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics, 103(4), 574-581.

XVII. Martin, M. A., Klein, T. E., Dong, B. J., Pirmohamed, M., Haas, D. W., & Kroetz, D. L. (2012). Clinical pharmacogenetics implementation consortium guidelines for HLA‐B genotype and abacavir dosing. Clinical Pharmacology & Therapeutics, 91(4), 734-738.

XVIII. Ahmed, A. F., Sukasem, C., Sabbah, M. A., Musa, N. F., Mohamed Noor, D. A., & Daud, N. A. A. (2021). Genetic determinants in HLA and cytochrome P450 genes in the risk of aromatic antiepileptic-induced severe cutaneous adverse reactions. Journal of Personalized Medicine, 11(5), 383.

XIX. Harr, T., & French, L. E. (2010). Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet journal of rare diseases, 5(1), 1-11.

XX. Lucia, L., Silvia, C., Paolo, B., Roberto, B., Fabio, C., Francesca, S., ... & Carlo, C. (2019). Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Bio Medica: Atenei Parmensis, 90(Suppl 3), 52.